US 12,661,335 B2
Halogenated xanthene-containing topical anti-gram-positive bacterial ophthalmic composition and method
Michio Kurosu, Knoxville, TN (US); Dominic Rodrigues, Knoxville, TN (US); Edward V. Pershing, Knoxville, TN (US); Bruce Horowitz, Knoxville, TN (US); John Lacey, III, Knoxville, TN (US); Eric A. Wachter, Oak Ridge, TN (US); and Edward P. Gamson, Highland Park, IL (US)
Assigned to Provectus Pharmatech, Inc., Knoxville, TN (US); and University of Tennessee Research Foundation, Memphis, TN (US)
Filed by Provectus Pharmatech, Inc., Knoxville, TN (US); and University of Tennessee Research Foundation, Memphis, TN (US)
Filed on Dec. 27, 2022, as Appl. No. 18/089,134.
Claims priority of provisional application 63/294,252, filed on Dec. 28, 2021.
Prior Publication US 2023/0270657 A1, Aug. 31, 2023
Int. Cl. A61K 8/81 (2006.01); A61K 31/352 (2006.01); A61N 5/06 (2006.01); A61P 31/04 (2006.01); C08F 220/58 (2006.01)
CPC A61K 31/352 (2013.01) [A61K 8/8158 (2013.01); A61N 5/062 (2013.01); A61P 31/04 (2018.01); C08F 220/585 (2020.02)] 7 Claims
 
1. A method of treating a mammalian subject having a Gram-positive bacterially-infected eye that exhibits keratitis consisting of the steps of treating said Gram-positive bacterially-infected eye by administering to that microbially-infected eye a keratitis-treating effective amount of an ophthalmic composition containing a halogenated fluorescein or pharmaceutically acceptable salt, amide or ester thereof dissolved or dispersed in an aqueous ophthalmic carrier and present in a bacterial keratitis-treating effective concentration of about 0.2 μg/mL to about 50 μg/mL in the composition, said ophthalmic composition having a pH value of about 6.5 to about 7.6, a viscosity of about 10 to about 300 cps and an osmolality of about 270 mOsm/kg to about 340 mOsm/kg, and maintaining said treated eye in the substantial absence of actinic light for a time period of about 3 to about 12 hours so that said treatment is carried out in the substantial absence of actinic light.